Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118116902 | 11811690 | 2 | F | 20160901 | 20151208 | 20160906 | EXP | CA-ROCHE-1670378 | ROCHE | 55.00 | YR | F | Y | 0.00000 | 20160906 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118116902 | 11811690 | 1 | PS | Pertuzumab | PERTUZUMAB | 1 | Unknown | U | 125409 | ||||||||||
| 118116902 | 11811690 | 2 | SS | Trastuzumab | TRASTUZUMAB | 1 | Unknown | U | 103792 | ||||||||||
| 118116902 | 11811690 | 3 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | U | 0 | ||||||||||
| 118116902 | 11811690 | 4 | SS | DOCETAXEL. | DOCETAXEL | 1 | Unknown | U | 0 | ||||||||||
| 118116902 | 11811690 | 5 | SS | Epirubicin | EPIRUBICIN | 1 | Intravenous (not otherwise specified) | U | 0 | ||||||||||
| 118116902 | 11811690 | 6 | SS | FLUOROURACIL. | FLUOROURACIL | 1 | Intravenous (not otherwise specified) | U | 0 | ||||||||||
| 118116902 | 11811690 | 7 | C | ADVIL | IBUPROFEN | 1 | Oral | 0 | 200 | MG | |||||||||
| 118116902 | 11811690 | 8 | C | ALEVE | NAPROXEN SODIUM | 1 | Oral | 0 | 220 | MG | QD | ||||||||
| 118116902 | 11811690 | 9 | C | GRAVOL | DIMENHYDRINATE | 1 | Oral | THERAPY DURATION: 4 DAYS | 0 | 50 | MG | QD | |||||||
| 118116902 | 11811690 | 10 | C | LOVENOX | ENOXAPARIN SODIUM | 1 | Subcutaneous | 0 | 40 | MG | QD | ||||||||
| 118116902 | 11811690 | 11 | C | MAXERAN | METOCLOPRAMIDE HYDROCHLORIDE | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 118116902 | 11811690 | 12 | C | SENOKOT | SENNOSIDES | 1 | Oral | 0 | 2 | DF | QD | ||||||||
| 118116902 | 11811690 | 13 | C | TYLENOL | ACETAMINOPHEN | 1 | Oral | 0 | |||||||||||
| 118116902 | 11811690 | 14 | C | TYLENOL | ACETAMINOPHEN | 1 | Oral | 0 | 500 | MG | |||||||||
| 118116902 | 11811690 | 15 | C | TYLENOL | ACETAMINOPHEN | 1 | Oral | THERAPY DURATION: 1 DAY | 0 | 1000 | MG | ||||||||
| 118116902 | 11811690 | 16 | C | TYLENOL | ACETAMINOPHEN | 1 | Oral | THERAPY DURATION: 4 DAYS | 0 | 325 | MG | QD | |||||||
| 118116902 | 11811690 | 17 | C | TYLENOL | ACETAMINOPHEN | 1 | Oral | THERAPY DURATION: 1 DAY | 0 | 1000 | MG | ||||||||
| 118116902 | 11811690 | 18 | C | VALACYCLOVIR | VALACYCLOVIR HYDROCHLORIDE | 1 | Topical | THERAPY DURATION: 5 DAYS | 0 | ||||||||||
| 118116902 | 11811690 | 19 | C | VALTREX | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | 0 | 500 | MG | QD | ||||||||
| 118116902 | 11811690 | 20 | C | VITAMIN C | ASCORBIC ACID | 1 | Oral | 0 | 500 | MG | QD | ||||||||
| 118116902 | 11811690 | 21 | C | VITAMIN D3 | CHOLECALCIFEROL | 1 | Oral | 0 | |||||||||||
| 118116902 | 11811690 | 22 | C | ZANTAC | RANITIDINE HYDROCHLORIDE | 1 | Oral | 0 | 150 | MG | QD | ||||||||
| 118116902 | 11811690 | 23 | C | ZOVIRAX | ACYCLOVIR | 1 | Topical | THERAPY DURATION: 3 DAYS | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118116902 | 11811690 | 1 | Product used for unknown indication |
| 118116902 | 11811690 | 2 | Product used for unknown indication |
| 118116902 | 11811690 | 3 | HER-2 positive breast cancer |
| 118116902 | 11811690 | 4 | Product used for unknown indication |
| 118116902 | 11811690 | 5 | HER-2 positive breast cancer |
| 118116902 | 11811690 | 6 | HER-2 positive breast cancer |
| 118116902 | 11811690 | 7 | Neuralgia |
| 118116902 | 11811690 | 8 | Neuralgia |
| 118116902 | 11811690 | 9 | Nausea |
| 118116902 | 11811690 | 10 | Antiphospholipid antibodies |
| 118116902 | 11811690 | 11 | Nausea |
| 118116902 | 11811690 | 12 | Constipation |
| 118116902 | 11811690 | 13 | Pyrexia |
| 118116902 | 11811690 | 14 | Headache |
| 118116902 | 11811690 | 18 | Oral herpes |
| 118116902 | 11811690 | 19 | Neuralgia |
| 118116902 | 11811690 | 20 | Product used for unknown indication |
| 118116902 | 11811690 | 21 | Product used for unknown indication |
| 118116902 | 11811690 | 22 | Prophylaxis |
| 118116902 | 11811690 | 23 | Oral herpes |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118116902 | 11811690 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118116902 | 11811690 | Abdominal pain upper | |
| 118116902 | 11811690 | Chills | |
| 118116902 | 11811690 | Diarrhoea | |
| 118116902 | 11811690 | Febrile neutropenia | |
| 118116902 | 11811690 | Gastrointestinal pain | |
| 118116902 | 11811690 | Hyperhidrosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |